MedPath

Preventive effect of pregabalin on oxaliplatin-related neurotoxicity for patients with advanced/recurrent colorectal cancer: a prospective phase 2 study

Phase 2
Recruiting
Conditions
Colorectal Cancer
Registration Number
JPRN-UMIN000009464
Lead Sponsor
Toyama Prefectural Central Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients who had received blood transfusion, blood products , or hematopoietic growth factors such as granulocyte-colony stimulating factor(G-CSF) within 7 days prior to registration 2)with brain metastasis 3)with much cavity fluid to be removed 4)with active double cancer 5)allergy against medicines 6)uncontrolled Hypertension 7)Prior or current thrapy for neuropathy or sensory dysfunction. 8)uncontrolled DM 9)active infection desease 10)watery diarrhea 11)disorderon EKG 12)severe respiratory disease(interstital pneumonitis,plumonary fibrosis,Severe pulmonary emphysema) 13)psychiatric disorder 14)fresh bleeding on the digestive tract 15)pregnant and/or nursing women 16)Doctor's stop not to be registered

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
eurotoxicity frequency of accumulation dose 500mg/m2 of L-OHP (Grade2 or more)
Secondary Outcome Measures
NameTimeMethod
1)Median dose of L-OHP 2)nerve disorder at the end of oxaliplatin-based regimen (each course Grade) 3)the psychometric properities of the FACT/GOG-Ntx 4)PFS and TTF 5)response rate
© Copyright 2025. All Rights Reserved by MedPath